Study of Psilocybin for Anorexia in Young Adults (SPANYA)

This interventional trial (n=40) will assess psilocybin therapy for refractory Anorexia Nervosa (anorexia, AN) in young adults.

The trial, sponsored by Marissa Raymond-Flesch, MD, MPH, and conducted at the University of California, San Francisco, will include three preparatory sessions, a 20mg psilocybin dosing session, two integration sessions, a 30mg psilocybin dosing session, and four final integration sessions.

Researchers hypothesise that psilocybin will increase cognitive flexibility, predicting long-term changes in cognitive rigidity, habitual eating, and exercise behaviours. Two family members of each participant will also be enrolled, with one attending portions of preparatory and integration sessions.

The primary outcome will be measured using the Eating Disorder Examination (EDE) questionnaire at various intervals up to one year post-treatment.

The study aims to provide insights into the efficacy of psilocybin-assisted therapy in treating Anorexia Nervosa.

Topic Eating Disorders
Compound Psilocybin
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

University of California San Francisco
At UCSF, there are two research teams dedicated to the study of psychedelics; the Neuroscape Psychedelic Division and the Translational Psychedelic Research Program.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.